TrialResults - center   -  Clinical trials results database in


Trials recently added - cardiology database

news feeds

14/11/2016 - EUCLID  -  versus

  cardiovascular prevention - antiplatelets drug - secondary prevention in patients with intermittent claudication

  peripheral vascular diseases - antiplatelets drug - all type of patient

02/05/2016 - IRIS  -  versus

  diabetes type 2 - glucose lowering for cardiovascular prevention - all type of patients

14/10/2015 - ABSORB II  -  everolimus-eluting bioresorbable scaffold (Absorb, Abbott Vascular) versus everolimus-eluting metallic stent (Xience, Abbott Vascular)

  percutaneous coronary intervention - bioresorbable vascular scaffold - all type of patients

14/10/2015 - LEADERS FREE  -  versus

  percutaneous coronary intervention - bioresorbable vascular scaffold - all type of patients

13/10/2015 - AVOID HF  -  versus

  acute heart failure - new drug under development - all type of patients

  acute heart failure - ultrafiltration - all type of patients

13/10/2015 - UNLOAD  -  versus

  acute heart failure - new drug under development - all type of patients

  acute heart failure - ultrafiltration - all type of patients

18/09/2015 - SUSTAIN 6  -  once-weekly semaglutide (0.5 mg or 1.0 mg) versus placebo

  diabetes type 2 - glucose lowering for cardiovascular prevention - all type of patients

16/09/2015 - SPRINT  -  target of 120 mm Hg versus target of 140 mm Hg

  hypertension - intensive blood pressure control - all type of patients

  hypertension - intensive blood pressure control - non diabetic patients

15/09/2015 - EMPA-REG OUTCOME  -  10 mg or 25 mg of empagliflozin once daily versus placebo

  diabetes type 2 - glucose lowering for cardiovascular prevention - all type of patients

01/05/2015 - CUPID 2b  -  Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) (Genetically Targeted Enzyme Replacement Therapy) versus

  heart failure - cell-based therapies - all types of patients

  heart failure - regenerative therapy - all type of patients

21/04/2015 - TOTAL  -  routine upfront manual thrombectomy versus PCI alone

  acute myocardial infarction - thrombectomy - all type of patients

  percutaneous coronary intervention - thrombectomy - patients with acute MI

15/03/2015 - FOURIER  -  versus

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

07/11/2014 - PEGASUS 60mg  -  ticagrelor at a dose of 60 mg twice daily versus placebo

  cardiovascular prevention - antiplatelets drug - all type of patients

  cardiovascular prevention - antiplatelets drug - secondary prevention in patients with CAD

  post myocardial infarction - antiplatelets drug - all type of patient

  cardiovascular prevention - antithrombotics - all type of patients

  cardiovascular prevention - antithrombotics - secondary prevention

31/08/2014 - SOLID-TIMI 52  -  versus

  cardiovascular prevention - cholesterol lowering intervention - patients with LDL elevation and without CHD

  cardiovascular prevention - cholesterol lowering intervention - patients with prior MI or with CHD

31/08/2014 - SIGNIFY  -  ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. versus placebo

  stable angina - HR-slowing agents - all type of patients

30/08/2014 - PARADIGM-HF  -  versus

  heart failure - combined inhibition of ACE and neprilysin - all type of patients

30/07/2014 - ODYSSEY Long-Term  -  alirocumab 150 mg as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. versus placebo

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY Alternative  -  Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY MONO  -  Alirocumab 75 mg Q2W versus Ezetimibe 10 mg

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY FH 1  -  Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Placebo

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY FH 2  -  Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Placebo

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY HIGH FH  -  Alirocumab 150 mg Q2W versus Placebo

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY OPTIONS I  -  Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - ODYSSEY OPTIONS II  -  Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - MENDEl 2  -  versus

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

30/07/2014 - DESCARTES  -  evolocumab (420 mg) every 4 weeks versus placebo

  cardiovascular prevention - PCSK9 Inhibitors - all type of patients

28/03/2014 - RELAX-AHF  -  48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation versus placebo (on top stnadard care)

  acute heart failure - new drug under development - all type of patients

  acute heart failure - relaxin - all type of patients

01/09/2013 - TASTE (Fröbert)  -  manual thrombus aspiration followed by PCI versus

  acute myocardial infarction - thrombectomy - all type of patients

  percutaneous coronary intervention - thrombectomy - patients with acute MI

30/08/2013 - ALECARDIO  -  versus

  diabetes type 2 - insulin sensitizer - all type of patients

  diabetes type 2 - insulin sensitizers - PPAR modulator - all types of patients

26/02/2013 - PREDIMED (olive oil)  -  Mediterranean diet supplemented with extra-virgin olive oil versus control diet (advice to reduce dietary fat)

  cardiovascular prevention - lifestyle intervention - all type of patients

  cardiovascular prevention - diet - all type of patients

13/02/2013 - TROPHI  -  thrombectomy versus

  acute myocardial infarction - thrombectomy - all type of patients

  percutaneous coronary intervention - thrombectomy - patients with acute MI

13/02/2013 - MUSTELLA  -  thrombectomy versus

  percutaneous coronary intervention - thrombectomy - patients with acute MI

09/01/2013 - CHAMPION PHOENIX  -  bolus and infusion of cangrelor followed by 600mg clopidogrel immediately post-infusion versus loading dose of 600 mg or 300 mg of clopidogrel

  percutaneous coronary intervention - antithrombotics - all type of patients

14/11/2012 - POSEIDON  -  allogeneic MSCs versus autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection

  heart failure - cell-based therapies - all types of patients



RSS news feeds

(c) 2006-2017TrialResults-center - All rights reserved Sitemap | Feedback | Disclaimer & Privacy Policy | Copyright | Home | Top
Learn how this site uses cookies at the Cookie Information page. Last uptaded on 2017/5
34 user(s) connected

Creative Commons License TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .


OpenSearch feed - Add TrialResults-center.org to your browser's search bar